Skip to main content
NovartisAcquisition

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Source: Autobound Signal API · 77 signals tracked for Novartis · updated

Get Novartis' live signals in Claude or ChatGPT, or by API

AskWhat changed at Novartis this week? Use Autobound signals for novartis.com.

What happened

Novartis has agreed to acquire Myricx Bio, a UK-based biotechnology company, for an upfront payment of $1.1 billion with an additional $400 million in potential milestone payments.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Basel, July 6, 2026 - Novartis today announced that it has entered into an agreement to acquire Myricx Bio ("Myricx"), a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates (ADCs), using N-myristoyltransferase inhibitor (NMTi) payloads. The proposed acquisition would strengthen the Novartis oncology pipeline and advance next-generation targeted drug conjugates with novel payload mechanisms. Myricx's approach is designed to deliver a differentiated cancer-killing payload directly to tumor cells, with the potential to address limitations of commonly used ADC payload classes such as TOPO-1 inhibitors. Myricx is developing two lead assets directed towards the targets B7-H3 and HER2, with potential across multiple solid tumor settings. "ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients," said Fiona Marshall, President of Biomedical Research at Novartis. "Myricx Bio has developed a promising NMTi payload platform with a differentiated mechanism that could broaden the use of ADCs across multiple tumor settings. This proposed acquisition reflects our strategy to scale innovative platforms, as we have with radioligand therapies, to deliver more durable, transformative treatments for patients." NMT is an enzyme that...

Keep reading with a free account

The rest of this article, and every signal for Novartis, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Acquisition

What this signalsIntegration work after a deal often opens needs for new systems and services.

Amount
$1.1B
Location
Basel, Basel-Stadt, Switzerland

Companies

  • Myricx BioTargetmyricxbio.com

More acquisition signals at other companies

The full record

From the Signal API record

Numbers

Amount (USD)
$1.1B

Extraction

Confidence
95%
Detected
Jul 7, 2026
signal_type
news
signal_subtype
acquires

Use this data

Get every acquisition signal for Novartis and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novartis this week?”

  2. Send it to your own tools

    The Signal API returns acquisition signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/b453334c-a13e-e752-8c24-dd58f36c6b51 returns this record as JSON. POST /v1/companies/enrich returns every signal for novartis.com.

{
  "signal_id": "b453334c-a13e-e752-8c24-dd58f36c6b51",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-07-07T19:52:30+00:00",
  "company": {
    "name": "Novartis",
    "domain": "novartis.com"
  },
  "data": {
    "url": "https://www.novartis.com/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients",
    "title": "Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients - Novartis",
    "excerpt": "Basel, July 6, 2026 - Novartis today announced that it has entered into an agreement to acquire Myricx Bio (“Myricx”), a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates (ADCs), using N-myristoyltransferase inhibitor (NMTi) payloads. The proposed acquisition would strengthen the Novartis oncology pipeline and advance next-generation targeted drug conjugates with novel payload mechanisms. Myricx’s approach is designed to deliver a differentiated cancer-killing payload directly to tumor cells, with the potential to address limitations of commonly used ADC payload classes such as TOPO-1 inhibitors. Myricx is developing two lead assets directed towards the targets B7-H3 and HER2, with potential across multiple solid tumor settings. “ADCs have become an important part of cancer treatment, but there remains a clear need for new payload mechanisms to overcome resistance and expand their impact for patients,” said Fiona Marshall, President of Biomedical Research at Novartis. “Myricx Bio has developed a promising NMTi payload platform with a differentiated mechanism that could broaden the use of ADCs across multiple tumor settings. This proposed acquisition reflects our strategy to scale innovative platforms, as we have with radioligand therapies, to deliver more durable, transformative treatments for patients.” NMT is an enzyme that...",
    "summary": "Novartis has agreed to acquire Myricx Bio, a UK-based biotechnology company, for an upfront payment of $1.1 billion with an additional $400 million in potential milestone payments.",
    "location": "Basel, Switzerland",
    "planning": true,
    "image_url": "https://www.novartis.com/sites/novartis_com/files/2023-11/novartis-animated-logo-1x.gif",
    "confidence": 0.95,
    "published_at": "2026-07-07T19:52:30Z",
    "location_data": [
      {
        "city": "Basel",
        "state": "Basel-Stadt",
        "region": "Western Europe",
        "country": "Switzerland",
        "continent": "Europe",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Novartis today announced that it has entered into an agreement to acquire Myricx Bio (“Myricx”), a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates (ADCs), using N-myristoyltransferase inhibitor (NMTi) payloads.",
    "amount_normalized": 1100000000,
    "related_company_name": "Myricx Bio",
    "related_company_domain": "myricxbio.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.